Table 1

Pharmacokinetic parameters of continuously IV-infused blinatumomab in the first treatment cycle of MRD+ ALL patients

AUC0-28, d × pg/mLAUC0-inf, d × pg/mLCss, pg/mLT1/2, β, hCL, L/d/m2VZ, L/m2
Mean ± SD19 659 ± 441319 764 ±4474731 ± 1631.250 ± 0.63422.3 ± 5.01.61 ±0.74
Range12 864-27 97912 914-28 135492-10500.52-2.7615.2-32.50.87-3.27
  • MRD indicates minimal residual disease; AUC, area under the curve; Css, steady-state serum concentration; T1/2,β, elimination serum half-life; CL, systemic clearance; and VZ, distribution volume.